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Purpose: To analyze the benefits, efficacy, and complications of the PASCAL® photocoagulation 
laser system (OptiMedica, Santa Clara, CA, USA) in patients treated at our institution.
Methods: We conducted a retrospective chart review of 19 patients (28 eyes) who underwent 
laser treatment using the PASCAL® photocoagulation system from November 2006 to November 
2007. These 28 eyes were divided into two groups; group 1 eyes underwent macular grid laser 
and group 2 eyes underwent panretinal photocoagulation. Treatment was performed for macular 
edema or for iris or retinal neovascularization. Outcomes measured included best-corrected 
visual acuity (BCVA), efficacy of laser treatment, complications, duration of the procedure, 
and pain perception, which were noted in the charts for panretinal treatments.
Results: Follow-up was 5.9 ± 2.6 months for group 1 and 5.9 ± 4.0 months for group 2. 
In group 1, 9/28 eyes required a second treatment for remaining edema. BCVA was stable or 
better in 66% (14/21) and average central foveal thickness on ocular coherence tomography 
improved in 71% (15/21). Time to completion for a number of laser patterns for grid photocoagu-
lation was felt to be too long for completing the total pattern safely, although we have not noted any 
related complications. In group 2, the neovascularization regressed at least partially in 3/7 patients. 
Patient-reported pain perception was 3.6 on a scale of 1 to 10 for group 2. Occasional hemorrhages 
occurred secondary to irregular laser uptake at different spots in the patterns. We observed no 
visual outcome consequences because of these hemorrhages during follow-up.
Conclusions: Retinal photocoagulation by the PASCAL® laser has comparable efficacy to 
historical results with conventional retinal photocoagulation in short-term follow-up. PASCAL® 
photocoagulation can be performed quicker with less discomfort for patients.
Keywords: diabetic retinopathy, laser, macular edema, PASCAL, patterned scan laser, photo-
coagulation, retinal neovascularization
Introduction
Laser photocoagulation in various forms is a standard of care procedure used in 
many retinal vascular disorders, including diabetic retinopathy and retinal vascular 
occlusions. Laser can be delivered with different machines and modalities (slit lamp, 
endolaser, indirect laser) at different wavelengths (532 to 810 nm) with varying 
parameters (power, spot size, duration, number of spots).
Conventional laser machines provide a single spot with the duration of each spot 
to be 50 ms or more. Spot size varies based on the treatment given; for example, 
grid and focal macular treatment spot size ranges from 50 to 100 and panretinal laser 
photocoagulation (PRP) from 200 to 500. The number of spots to be placed also varies 
for each condition; often times, macular lasers require 10 to 100 spots in each sitting Clinical Ophthalmology 2009:3 466
Modi et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and panretinal lasers require 700 to 1500 spots per treatment 
by conventional laser.
Macular laser treatments occasionally may be painful and 
retrobulbar anesthesia may be needed. Pain is associated with 
positional placement of spots; the patient perceives more pain 
the more anterior (peripheral) the spots are placed.1 Horizontal 
placement of spots is also more painful since this is the area 
of passage of the posterior ciliary nerves.1 Other parameters 
causing increased pain include longer duration, larger spot 
size, previous laser sessions, and higher wavelength.1
A macular laser procedure usually takes minutes to 
complete, while a PRP may take 20 to 30 minutes, based on 
patient cooperation, surgeon experience, and the size of the 
treatment area.
New laser delivery methods using retinal tracking 
systems and predetermined laser patters have been widely 
studied. Patterned scan laser (PASCAL®; OptiMedica Corp., 
Santa Clara, CA, USA) was introduced in 2006 and uses a 
technology based on the use of a semi-automated application 
of 532 nm laser pulses in a predetermined pattern and rapid 
sequence. Using this device, 0 to 2000 mW frequency-doubled 
Nd:YAG diode laser energy can be applied at 10 to 1000 ms 
pulses with 10-ms intervals.2 With this technique, more evenly 
distributed laser burns can be placed in a shorter period of 
time. The shorter duration also is suggestive of less pain 
experienced by patients. Another proposed advantage includes 
higher precision, especially for macular grid lasers, due to the 
fixation beam that allows patients to remain steady.
Here, we report our experience in treating diabetic 
retinopathy and retinal vascular occlusions using the 
PASCAL® within a 1-year time period.
Material and methods
During the period November 2006 to November 2007, 
19 patients at O’Donnell Eye Institute were treated with 
PASCAL® photocoagulation (Figure 1). This retrospective 
Figure 1 The PAsCAL® system is mounted on a slit lamp. The slit lamp table dimensions are 122 cm wide by 76 cm deep by 71 to 96 cm high.   The height of the table can 
be easily controlled to adjust for patients’ height and body habitus. OptiMedica states that the slit lamp table is also wheelchair accessible.   We have found it to be wheelchair 
accessible, but still does not entirely fit the extremes of patients’ height and body habitus.   A. Touch-screen used to control PASCAL. B. Pattern options for treatment. C. Side 
profile of PASCAL. D. Patient’s view of PASCAL.Clinical Ophthalmology 2009:3 467
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chart review included 28 eyes that were divided into 
two groups based on whether they needed treatment 
for macular edema or for iris or retinal neovasculariza-
tion secondary to diabetic retinopathy or other ischemic 
retinal vascular disorders. Macular edema was measured 
pre- and postoperatively at each visit by Stratus Ocular 
Coherence Tomography (OCT) (Carl Zeiss Meditec Inc., 
Dublin, CA, USA).
Our outcome measures were noted by best corrected 
visual acuity (BCVA), efficacy of laser treatment, duration 
of the laser treatment, and pain perception. BCVA was 
converted to logMAR for statistical analysis and then con-
verted back to Snellen acuity for the ease of interpretation. 
Efficacy of laser treatment was measured by 1) a decrease in 
macular edema using OCT if treatment was aimed at macular 
edema, or 2) regression in neovascularization of the iris or 
retina if treatment was aimed at ocular ischemic vascular 
disorders. Patients that received PRP were asked to report 
their pain perception on a scale of 1 to 10, 10 being the most 
severe. Topical proparacaine was used for local anesthesia 
prior to performing the procedure.
Results
Group 1 consisted of 12 patients and 21 eyes. Grid laser was 
performed in these 21 eyes (Figure 2). Of these, macular 
edema was secondary to diabetic retinopathy in 18 of the 
21 eyes and secondary to branch retinal vein occlusion 
(BRVO) is 3 of the 21 eyes. The mean pre-laser BCVA 
was 20/54 and mean post-laser best-corrected visual acuity 
was 20/56. Average central foveal thickness (CFT) was 
used as the main indicator of increased macular edema or 
decreased macular edema. CFT improved in 71% (15/21) 
eyes (Table 1).
Group 2 consisted of seven patients (seven eyes) 
receiving panretinal photocoagulation during a single 
session because of neovascularization of the retina or iris 
secondary to ischemic retinal disorders (Figure 3). Six of 
the seven patients received PRP because of proliferative 
diabetic retinopathy and one of the seven patients received 
PRP because of neovascularization from a past history of 
central retinal vein occlusion (CRVO). For these patients, 
pre-laser BCVA was 20/94 and post-laser BCVA was 20/97. 
Neovascularization at least partially regressed in three of the 
seven patients.
In group 2, five of the seven patients were asked to rate 
procedural pain. The average pain felt by these five patients 
averaged 3.6 using only topical proparacaine as anesthesia. 
The average number of spots used was 1326, the maximum 
Figure 2 grid laser with PAsCAL®.
Table 1 Treatment of macular edema with PAsCAL®




number of patients 12 7
number of eyes 21 7
Average pre-laser BCVA 20/54 20/94
Average post-laser BCVA 20/56 20/97
Average pain n/A 3.6
number of eyes with  
complicationsa
2  2 
aComplications include retinal hemorrhages.
Abbreviations: BCVA, best-corrected visual acuity.
Figure 3 Panretinal photocoagulation.Clinical Ophthalmology 2009:3 468
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number used being 1825. All PRP sessions took less than 
5 minutes of laser time.
Of the 28 eyes examined, there were two complications 
in our patients; retinal hemorrhage occurred secondary to 
too high of a power being used within the pattern (Figure 4). 
These minor hemorrhages did not, however, reflect upon 
the patients’ visual acuity in our study. No new choroidal 
neovascularization occurred from these intense burns. 
Inconsistencies in uptake during PRP occurred when different 
patterns were used.
Discussion and conclusion
Laser photocoagulation remains the gold standard in the 
treatment of many retinal vascular disorders. Conventional 
photocoagulation uses a single application of laser energy 
per laser shot. PASCAL® system uses a multitude of patterns 
including square arrays, single arc, and full and partial 
macular grid, although also capable of single spot laser. 
Pan-retinal photocoagulation for proliferative diabetic reti-
nopathy and macular grid for diabetic macular edema are the 
primary applications; however, patterns can be applied for 
other retinal vascular disorders and retinal tears.
Sanghvi et al describe panretinal photocoagulation done 
with conventional one-spot laser versus the multiple-spot 
pattern laser done with the PASCAL®.2 Twenty-two patients 
had both types of methods used in the same eye. The mean 
power was 235 mW for the conventional laser method 
versus 396 mW for the PASCAL® to achieve the same type 
of laser burn.2 This was thought to be due to a much shorter 
duration of laser exposure time used by the PASCAL®. Also, 
when comparing PRP done by conventional laser versus 
PASCAL® on the same eye, the patient received many more 
laser spots in the PASCAL® group, with a mean of 738 to 
1116 spots respectively.2 This was thought to be a result of 
better toleratance of the laser spots in the PASCAL® group 
because of the shorter exposure time of the laser. Similarly, 
in patients who had undergone laser treatment for macular 
edema, the PASCAL® group used more power, again due 
to a shorter exposure time of the laser. However, the power 
levels required with the PASCAL® system did not result in 
any complications in that study. In our experience perform-
ing grid and PRP with the PASCAL® we realized that retinal 
hemorrhages were common because of irregular uptake. Yet, 
this resulted in no significant complications other than a few 
days of floaters voiced by the patients.3
Blumenkranz et al noted that the power required to 
produce ophthalmoscopically visible spots decreased with 
increasing pulse duration.4 In their experiments, cumulative 
pulse energy increased with pulse duration, indicating a 
significant diffusion of heat from the laser spot with pulse 
durations greater than 20 ms, which is typically longer than 
the duration used in the PASCAL® system. Also noted was 
creation of less homogenized and less localized lesions 
with longer pulses. At 20 ms pulse duration, the threshold 
power for producing a visible lesion was 110 mW to 
120 mW and the threshold for hemorrhage was 600 mW.4 
Blumenkranz et al also estimated the time to place 16 laser 
spots at one application and the time to place 36 spots of 
laser at one application with pulse durations of 10 ms, 
20 ms, 50 ms, and 100 ms.4 They estimated that it may be 
possible to reduce total laser application time by a factor of 
7- to 10-fold using these pattern arrays rather than single 
spot photocoagulation. With these data, a PRP can poten-
tially be done in one sitting rather than multiple sittings 
with the conventional laser method. Potential advantages 
over conventional single-spot photocoagulation include 
improved efficiency, increased uniformity and precision 
of spot placement, and possibly reduced pain and visual 
field defects because of reduced heat diffusion toward the 
choroid and inner retina.3
However, in the DRS and ETDRS, recommendations 
are that no more than 900 applications per session be used, 
separated in time by 2 weeks because of the potential for 
complications such as macular edema, choroidal detachment, 
exudative retinal detachment, and shallowing or closure of the 
Figure 4 Retinal hemorrhage and leak into the vitreous from a single laser spot in 
the superior aspect of the retina where grid laser was performed.Clinical Ophthalmology 2009:3 469
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anterior chamber angle.5,6 Single versus multiple treatment 
sessions using argon laser for PRP caused by proliferative 
diabetic retinopathy was done and visual acuity was assessed 
after PRP in both the multiple- and single-treatment groups; 
no difference between both groups was seen in final visual 
acuity.6 Prior to treatment, all patients had high risk for 
severe visual loss with three of four retinopathy risk factors.2 
Six months after treatment, only 40% of the single treatment 
group versus 36% of the multiple treatment group was in the 
same high-risk category.7 When compared, the single- and 
multiple-treatment groups were of equal efficacy in reducing 
the number of retinopathy risk factors.7 Also, in this study 
there did not appear to be a marked difference between 
single- and multiple-treatment session groups in regression 
of neovascularization of the optic disc. A higher incidence 
of exudative retinal detachment, choroidal detachment, and 
angle closure occurred in the single treatment group eyes than 
in the multiple treatment group eyes.8 All of these complica-
tions resolved spontaneously within a short period of time 
after treatment and visual loss that was acquired from these 
complications were only transient.8
Jain et al demonstrated that shorter pulse durations 
decreased the width and axial extent of the retinal lesions.9 
There was less collateral damage with less spread of heat 
to adjacent retina and choroid. The PASCAL® system uses 
durations in this range, and with the less spread of heat to the 
adjacent retina and choroid with the shorter duration, even 
one sitting PRP sessions may not have significant transient 
choroidal or retinal detachments. Clinical efficacy in the long 
term remains to be studied.
Al-Hussainy et al used an ND:YAG laser with a 
wavelength of 532 nm with shorter duration exposures to 
determine if this was more comfortable for patients than 
conventional parameters.1 Their study compared exposure 
times of 0.1 seconds with a duration of 0.02 seconds. The 
group that had a longer exposure time required less power 
averaging 0.178 W compared to the shorter duration group 
needing 0.49 W.1 These patients were asked to rate their 
pain perception on a scale of 0 to 10 with 0 being no pain 
and 10 being the most pain they have ever experienced. The 
patients with the longer exposure time rated the pain on 
average to be 5.11. The patients with the shorter duration 
time rated the pain to be on average 1.41. This was found 
to be statistically significant.9 The PASCAL® system uses 
the same laser and uses this shorter duration of action. The 
mode of delivery that the PASCAL® system uses looks 
highly promising in decreasing patient pain during PRP. 
In our study, 90% of the patients reported a pain perception 
3.6 with a range from 2 to 9 using a pain scale from 1 to 10, 
10 being the most severe pain.3
As we have discussed previously, laser-tissue interaction 
is influenced by wavelength, spots size, power, and exposure 
time. According to our experiences as well as other studies, 
a higher power is required to produce the desired lesion on 
the retina. Sanghvi et al did not observe any complications.2 
However, retinal hemorrhages from macular photocoagulation 
and PRP due to irregular uptake from differing amounts 
of pigmentation of the retina, differences in media clarity, 
and differences in the focusing distance among the spots 
occurred. Yet, this resulted in no significant complications 
other than a few days of floaters voiced by the patients.2 
Laser complications such as this needs to be meticulously 
investigated further to reduce such complications. Some 
of the pattern and parameter alternatives readily presented 
currently in the software need to be modified for the safest 
applications.10
PASCAL® photocoagulation can be performed quicker 
with less discomfort for the patients. Follow-up for this study 
was less than a year for both groups. The results of both of 
these groups show equal efficacy to traditional 1-spot laser. 
However, further long-term follow-up needs to be done. 
Also, only 28 eyes were used in this group. A larger study 
needs to be done in the future to better understand further 
the benefits and disadvantages of using this system.
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